Want to see JP:4574 full AI Analyst Report?
Taiko Pharmaceutical Co., Ltd. (4574) Ratios
Taiko Pharmaceutical Co., Ltd. Ratios
JP:4574's free cash flow for Q2 2026 was $0.00. For the 2026 fiscal year, JP:4574's free cash flow was increased by $0.00 and operating cash flow was $0.00. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.36 | 3.07 | 2.99 | 2.71 | 3.19 |
| Quick Ratio | 2.72 | 2.48 | 2.54 | 2.01 | 2.45 |
| Cash Ratio | 1.70 | 1.59 | 1.80 | 1.11 | 1.34 |
| Solvency Ratio | 0.32 | 0.23 | -0.45 | -0.79 | -1.05 |
| Operating Cash Flow Ratio | 0.32 | 0.13 | -0.10 | -0.71 | -0.37 |
| Short-Term Operating Cash Flow Coverage | 1.01 | 0.30 | -0.25 | -1.87 | -1.66 |
| Net Current Asset Value | $ 4.68B | $ 3.81B | $ 2.63B | $ 553.00M | $ 4.05B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.07 | 0.16 | 0.25 | 0.25 | 0.21 |
| Debt-to-Equity Ratio | 0.10 | 0.25 | 0.48 | 0.47 | 0.37 |
| Debt-to-Capital Ratio | 0.09 | 0.20 | 0.33 | 0.32 | 0.27 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.09 | 0.23 | 0.25 | 0.23 |
| Financial Leverage Ratio | 1.44 | 1.62 | 1.96 | 1.87 | 1.76 |
| Debt Service Coverage Ratio | 0.85 | 1.00 | -2.39 | -3.50 | -6.50 |
| Interest Coverage Ratio | 91.80 | 78.63 | -125.63 | -307.90 | -824.67 |
| Debt to Market Cap | 0.05 | 0.12 | 0.22 | 0.22 | 0.13 |
| Interest Debt Per Share | 16.34 | 40.55 | 68.88 | 87.59 | 109.84 |
| Net Debt to EBITDA | -4.75 | -2.84 | 0.78 | -0.19 | 0.18 |
| Profitability Margins | |||||
| Gross Profit Margin | 54.42% | 58.26% | 42.11% | 21.41% | 25.62% |
| EBIT Margin | 7.18% | 9.95% | -58.09% | -61.09% | -46.16% |
| EBITDA Margin | 11.32% | 14.02% | -46.58% | -74.40% | -51.94% |
| Operating Profit Margin | 7.18% | 10.00% | -16.42% | -61.09% | -46.16% |
| Pretax Profit Margin | 14.98% | 8.98% | -58.22% | -96.61% | -82.90% |
| Net Profit Margin | 14.43% | 14.27% | -59.00% | -97.10% | -89.49% |
| Continuous Operations Profit Margin | 14.44% | 14.27% | -58.99% | -97.10% | -89.49% |
| Net Income Per EBT | 96.35% | 158.94% | 101.35% | 100.51% | 107.94% |
| EBT Per EBIT | 208.71% | 89.83% | 354.53% | 158.14% | 179.61% |
| Return on Assets (ROA) | 7.52% | 6.95% | -27.31% | -32.53% | -42.57% |
| Return on Equity (ROE) | 10.84% | 11.28% | -53.59% | -60.85% | -74.92% |
| Return on Capital Employed (ROCE) | 4.70% | 6.25% | -9.88% | -25.13% | -27.16% |
| Return on Invested Capital (ROIC) | 4.19% | 5.57% | -8.81% | -23.12% | -25.81% |
| Return on Tangible Assets | 7.54% | 6.97% | -27.32% | -33.01% | -43.14% |
| Earnings Yield | 6.17% | 5.41% | -25.16% | -28.49% | -26.76% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.61 | 2.59 | 3.08 | 2.80 | 2.64 |
| Payables Turnover | 6.91 | 2.49 | 9.45 | 14.46 | 25.80 |
| Inventory Turnover | 1.80 | 1.57 | 2.58 | 2.03 | 2.49 |
| Fixed Asset Turnover | 1.93 | 1.92 | 1.71 | 0.79 | 1.51 |
| Asset Turnover | 0.52 | 0.49 | 0.46 | 0.33 | 0.48 |
| Working Capital Turnover Ratio | 1.08 | 1.05 | 1.13 | 0.71 | 0.98 |
| Cash Conversion Cycle | 289.50 | 227.16 | 221.20 | 284.84 | 270.68 |
| Days of Sales Outstanding | 139.79 | 140.85 | 118.39 | 130.21 | 138.10 |
| Days of Inventory Outstanding | 202.53 | 232.82 | 141.45 | 179.87 | 146.72 |
| Days of Payables Outstanding | 52.82 | 146.50 | 38.63 | 25.25 | 14.15 |
| Operating Cycle | 342.32 | 373.66 | 259.83 | 310.09 | 284.82 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 16.20 | 7.21 | -6.48 | -45.73 | -36.66 |
| Free Cash Flow Per Share | 10.41 | 4.09 | -8.89 | -47.66 | -73.43 |
| Dividend Paid and CapEx Coverage Ratio | 1.78 | 2.29 | -2.67 | -23.74 | -0.67 |
| Capital Expenditure Coverage Ratio | 2.80 | 2.31 | -2.69 | -23.74 | -1.00 |
| Operating Cash Flow Coverage Ratio | 1.00 | 0.18 | -0.09 | -0.52 | -0.33 |
| Operating Cash Flow to Sales Ratio | 0.13 | 0.06 | -0.05 | -0.40 | -0.15 |
| Free Cash Flow Yield | 3.49% | 1.23% | -2.93% | -12.10% | -8.91% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 16.22 | 18.50 | -3.97 | -3.51 | -3.74 |
| Price-to-Sales (P/S) Ratio | 2.34 | 2.64 | 2.34 | 3.41 | 3.34 |
| Price-to-Book (P/B) Ratio | 1.76 | 2.09 | 2.13 | 2.14 | 2.80 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 28.62 | 81.03 | -34.09 | -8.27 | -11.22 |
| Price-to-Operating Cash Flow Ratio | 18.39 | 45.89 | -46.74 | -8.62 | -22.48 |
| Price-to-Earnings Growth (PEG) Ratio | 6.05 | -0.15 | 0.12 | 0.07 | 0.01 |
| Enterprise Value Multiple | 15.93 | 15.99 | -4.25 | -4.77 | -6.26 |
| Enterprise Value | 11.53B | 14.11B | 12.12B | 17.88B | 34.83B |
| EV to EBITDA | 15.93 | 15.99 | -4.25 | -4.77 | -6.26 |
| EV to Sales | 1.80 | 2.24 | 1.98 | 3.55 | 3.25 |
| EV to Free Cash Flow | 22.05 | 68.81 | -28.79 | -8.61 | -10.90 |
| EV to Operating Cash Flow | 14.17 | 38.97 | -39.48 | -8.97 | -21.84 |
| Tangible Book Value Per Share | 168.96 | 158.22 | 142.25 | 179.37 | 287.43 |
| Shareholders’ Equity Per Share | 169.56 | 158.70 | 142.27 | 184.46 | 294.31 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.04 | -0.59 | -0.01 | -0.01 | -0.08 |
| Revenue Per Share | 127.34 | 125.38 | 129.22 | 115.59 | 246.39 |
| Net Income Per Share | 18.37 | 17.89 | -76.25 | -112.24 | -220.48 |
| Tax Burden | 0.96 | 1.59 | 1.01 | 1.01 | 1.08 |
| Interest Burden | 2.09 | 0.90 | 1.00 | 1.58 | 1.80 |
| Research & Development to Revenue | 0.00 | 0.03 | 0.04 | 0.00 | 0.00 |
| SG&A to Revenue | 0.47 | 0.45 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.88 | 0.40 | 0.09 | 0.41 | 0.18 |
Currency in JPY
